查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2080170

全球數位病理市場：按產品、類型、工作流程、應用和最終用戶分類－市場規模、產業動態、機會分析和預測（2026-2035 年）

Global Digital Pathology Market By Product, Type, Workflow, Application, End User - Market Size, Industry Dynamics, Opportunity Analysis and Forecast For 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 260 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球數位病理市場正經歷快速且變革性的擴張，反映出現代診斷服務在醫療保健系統中交付方式的根本性變化。該市場預計在2025年達到約15億美元，並預計在2035年顯著成長至約85億美元。這一成長意味著在2026年至2035年的預測期內，複合年成長率將達到約18.9%。

這一上升趨勢主要源自於全球慢性病負擔的日益加重，這持續對醫療基礎設施造成巨大壓力。癌症、心血管疾病、糖尿病和其他慢性病等疾病需要頻繁、準確和詳細的診斷評估，而這些評估大多依賴病理服務。隨著患者數量的增加和疾病複雜性的提高，醫療機構正擴大採用數位化病理解決方案，以提高效率、縮短週轉時間並增強診斷準確性。

顯著的市場趨勢

數位病理市場由少數幾家全球領導者組成，這些企業攜手合作，推動整個醫療保健系統的創新、應用和技術進步。丹納赫公司（Danaher Corporation）及其子公司徠卡生物系統（Leica Biosystems）是該市場最具影響力的公司之一。該公司透過大力投資研發和有針對性的收購來拓展自身能力，從而推動市場成長。

皇家飛利浦公司已成為領先的雲端數位病理解決方案供應商。其IntelliSite平台旨在實現無縫的全切片成像和工作流程管理，使病理學家能夠有效率地存取和分析數位切片。羅氏公司則憑藉其Ventana部門，提供結合先進染色技術和高解析度掃描系統的綜合組織診斷解決方案。

濱松光子學專注於成像硬體的創新，尤其以其高解析度全玻片掃描器「NanoZoomer」系列而聞名。該公司以注重光學精度、可靠性和掃描效率而著稱，其系統廣泛應用於科研機構和臨床檢查室。 3DHISTECH透過提供專為診斷和科學研究應用客製化的數位病理掃描儀和軟體解決方案，維持其市場競爭優勢。

主要成長要素

全球慢性病負擔日益加重是推動數位病理市場成長的主要動力。世界各地的醫療保健系統正面臨長期、複雜疾病盛行率不斷上升的挑戰，這些疾病需要準確、快速且詳細的診斷評估。這一趨勢顯著增加了對能夠處理大量組織樣本並保持診斷準確性和一致性的先進病理解決方案的需求。隨著慢性病發病率和複雜性的持續增加，數位病理已成為支持現代診斷工作流程的重要工具。

新機會的趨勢

人工智慧 (AI) 與機器學習的融合是推動數位病理市場成長的一大新興機會。由於數位病理系統會產生大量的高解析度影像數據，因此，人工智慧技術的應用日益廣泛，旨在更有效率、更準確地分析和解讀這些資訊。這些先進的演算法能夠檢測出僅靠人工檢查難以發現的組織樣本中的細微異常，從而提高診斷準確性，並有助於獲得更一致的臨床結果。

最佳化障礙

高額資本投入預計將成為限制數位病理市場成長的主要阻礙因素。儘管這項技術在診斷效率、工作流程最佳化和資料可近性方面具有顯著的長期效益，但其實施需要大量的初期投資。醫療機構不僅需要為成像硬體分配大量預算，還需要為配套基礎設施、軟體系統、儲存解決方案和人員培訓分配預算。這構成了較高的初始准入門檻，尤其對於資金緊張的小規模醫院、診斷中心和檢查室而言更是如此。

目錄

第1章執行摘要：全球數位病理市場

第2章：調查方法與研究框架

  • 研究目標
  • 產品概述
  • 市場區隔
  • 定性研究
    • 一手和二手資訊
  • 量化研究
    • 一手和二手資訊
  • 主要調查受訪者組成：按地區分類
  • 本研究的前提
  • 市場規模估算
  • 數據三角測量

第3章：全球數位病理市場概覽

  • 產業價值鏈分析
  • 產業展望
    • 全球數位計算病理學產業概覽
    • 人工智慧輔助診斷、全切片影像和遠端病理的實施現況。
    • 病理學家短缺、法規核准、保險報銷趨勢。
  • PESTLE分析
  • 波特五力分析
  • 市場成長及前景
    • 2020-2035年市場收入估算與預測
    • 價格趨勢分析：依產品分類

第4章：全球數位病理市場分析

  • 競爭對手儀錶板
    • 市場集中度
    • 企業市場占有率分析，2025 年
    • 競爭對手分析與基準測試

第5章：全球數位病理市場分析

  • 市場動態和趨勢
    • 成長促進因素
    • 抑制因子
    • 機會
    • 主要趨勢
  • 市場規模及預測，2020-2035年
    • 依產品
      • 關鍵見解
        • 硬體
          • 掃描器/全幻燈片成像
          • 滑軌管理硬體
        • 軟體
          • 影像管理
          • 人工智慧/計算病理學
        • 服務和儲存
    • 按類型
      • 關鍵見解
        • 人類病理學
        • 獸醫病理學
    • 基於工作流程
      • 關鍵見解
        • 初步診斷
        • 遠距病理諮詢/遠距病理學
        • 研究/教育
    • 透過使用
      • 關鍵見解
        • 診斷
        • 藥物發現與開發
        • 學術研究
        • 培訓和教育
    • 最終用戶
      • 關鍵見解
        • 醫院/診斷檢查室
        • 製藥和生物技術
        • 學術研究機構
        • CRO
    • 按地區
      • 關鍵見解
        • 北美洲
          • 美國
          • 加拿大
          • 墨西哥
        • 歐洲
          • 西歐
            • 英國
            • 德國
            • 法國
            • 義大利
            • 西班牙
            • 其他西歐國家
          • 東歐
            • 波蘭
            • 俄羅斯
            • 其他東歐國家
        • 亞太地區
          • 中國
          • 印度
          • 日本
          • 澳洲和紐西蘭
          • 韓國
          • ASEAN
          • 其他亞太國家
        • 中東和非洲（MEA）
          • 沙烏地阿拉伯
          • 南非
          • UAE
          • 其他中東和非洲國家
        • 南美洲
          • 阿根廷
          • 巴西
          • 其他南美國家

第6章：北美市場分析

第7章：歐洲市場分析

第8章：亞太市場分析

第9章：中東和非洲市場分析

第10章：南美市場分析

第11章：公司簡介

  • 3DHISTECH Ltd.
  • Apollo Enterprise Imaging Corp
  • Hamamatsu Photonics KK
  • Hoffmann-La Roche Ltd.
  • Huron Technologies International Inc.
  • Koninklijke Philips NV
  • Sectra AB
  • Thermo Fisher Scientific Inc.
  • 其他主要公司

第12章附錄

簡介目錄
Product Code: AA06261849

The global digital pathology market is undergoing rapid and transformative expansion, reflecting a fundamental shift in how modern diagnostic services are delivered across healthcare systems. The market is estimated to be valued at approximately USD 1.5 billion in 2025 and is projected to grow significantly, reaching around USD 8.5 billion by 2035. This growth corresponds to a strong compound annual growth rate (CAGR) of about 18.9% over the forecast period from 2026 to 2035.

This upward trajectory is primarily driven by the increasing global burden of chronic diseases, which continues to place significant pressure on healthcare infrastructure. Conditions such as cancer, cardiovascular disorders, diabetes, and other long-term illnesses require frequent, accurate, and detailed diagnostic evaluation, much of which depends on pathology services. As patient volumes rise and disease complexity increases, healthcare providers are increasingly turning to digital pathology solutions to improve efficiency, reduce turnaround times, and enhance diagnostic accuracy.

Noteworthy Market Developments

The digital pathology market is shaped by a small group of leading global players that collectively drive innovation, adoption, and technological advancement across healthcare systems. Danaher Corporation is one of the most influential players in the market, primarily through its subsidiary Leica Biosystems. The company drives growth by investing heavily in research and development and expanding its capabilities through targeted acquisitions.

Koninklijke Philips N.V. has established itself as a major provider of integrated, cloud-based digital pathology solutions. Its IntelliSite platform is designed to enable seamless whole-slide imaging and workflow management, allowing pathologists to access and analyze digital slides efficiently. F. Hoffmann-La Roche Ltd leverages its Ventana division to deliver comprehensive tissue diagnostics solutions that combine advanced staining technologies with high-resolution scanning systems.

Hamamatsu Photonics focuses strongly on imaging hardware innovation, particularly through its NanoZoomer series of high-resolution whole-slide scanners. The company is known for its emphasis on optical precision, reliability, and scanning efficiency, making its systems widely adopted in research institutions and clinical laboratories. 3DHISTECH maintains a competitive position in the market by offering a specialized portfolio of digital pathology scanners and software solutions tailored for diagnostic and research applications.

Core Growth Drivers

The rising global burden of chronic diseases is a major factor driving growth in the digital pathology market. Across the world, healthcare systems are facing an increasing prevalence of long-term and complex medical conditions that require accurate, timely, and detailed diagnostic evaluation. This trend has significantly increased the demand for advanced pathology solutions capable of handling high volumes of tissue samples while maintaining diagnostic precision and consistency. As chronic diseases continue to grow in both incidence and complexity, digital pathology has become an essential tool in supporting modern diagnostic workflows.

Emerging Opportunity Trends

The integration of artificial intelligence (AI) and machine learning represents a major emerging opportunity driving growth in the digital pathology market. As digital pathology systems generate large volumes of high-resolution image data, AI technologies are increasingly being deployed to analyze and interpret this information more efficiently and accurately. These advanced algorithms are capable of detecting subtle abnormalities in tissue samples that may be difficult to identify through manual examination alone, thereby enhancing diagnostic precision and supporting more consistent clinical outcomes.

Barriers to Optimization

High capital expenditure is expected to act as a significant constraint on the growth of the digital pathology market. While the technology offers substantial long-term benefits in terms of diagnostic efficiency, workflow optimization, and data accessibility, its adoption requires considerable upfront financial investment. Healthcare institutions must allocate substantial budgets not only for imaging hardware but also for supporting infrastructure, software systems, storage solutions, and workforce training. This creates a high initial barrier to entry, particularly for smaller hospitals, diagnostic centers, and laboratories operating under tight financial constraints.

Detailed Market Segmentation

By type, the human pathology segment dominates the digital pathology market with an overwhelming 92% share as of 2025. This substantial concentration highlights the central role of human tissue analysis in modern medical diagnostics and clinical decision-making. The segment's dominance is primarily driven by the increasing global burden of diseases such as cancer, cardiovascular conditions, and other chronic illnesses, all of which require detailed histopathological evaluation for accurate diagnosis and effective treatment planning. As a result, human pathology remains the core application area where digital pathology technologies are most extensively deployed.

By workflow, primary diagnosis represents the dominant segment in the digital pathology market, accounting for approximately 62% of total market share. This strong position highlights its growing acceptance as the core function of digital pathology systems within clinical practice. Primary diagnosis involves the initial and definitive interpretation of tissue samples to identify diseases, determine severity, and guide treatment decisions. As healthcare systems increasingly transition toward digital platforms, this workflow has become the central focus of adoption, reflecting its critical importance in patient care pathways.

By end user, hospitals and diagnostic laboratories dominate the digital pathology market, accounting for a significant 65% share. This leadership reflects their central role in clinical diagnostics and the high-volume nature of pathology workflows handled within these large healthcare systems. As primary points of patient care and disease diagnosis, hospitals and diagnostic laboratories process vast numbers of tissue samples on a daily basis, making them the most critical users of digital pathology solutions. The adoption of digital platforms in these settings has become essential for improving efficiency, turnaround time, and diagnostic accuracy.

By application, the diagnostics segment holds a dominant position in the digital pathology market, accounting for approximately 48% of the total market share in 2025. This leadership reflects the central role that diagnostic workflows play in modern clinical decision-making, particularly as healthcare systems increasingly rely on digital tools to improve accuracy, efficiency, and accessibility in pathology services. The widespread adoption of digital pathology platforms has significantly enhanced the ability of clinicians to analyze tissue samples with greater precision, enabling faster and more reliable diagnostic outcomes across a range of disease areas.

Segment Breakdown

By Product

  • Hardware
  • Scanners/Whole-Slide Imaging
  • Slide Management Hardware
  • Software
  • Image Management
  • AI/Computational Pathology
  • Services & Storage

By Type

  • Human Pathology
  • Veterinary Pathology

By Workflow

  • Primary Diagnosis
  • Consultation/Telepathology
  • Research & Education

By Application

  • Diagnostics
  • Drug Discovery & Development
  • Academic Research
  • Training & Education

By End User

  • Hospitals & Diagnostic Labs
  • Pharma & Biotech
  • Academic & Research Institutes
  • CROs

By Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America

Geography Breakdown

  • North America holds a dominant position in the global digital pathology market, accounting for approximately 41% of the total market share in 2026. This leadership is strongly supported by the region's highly advanced healthcare infrastructure and the widespread adoption of enterprise-scale laboratory digitization. Healthcare systems across the United States and Canada have been early adopters of medical imaging technologies, enabling a faster transition from traditional pathology practices to fully digital workflows.
  • A major factor reinforcing North America's dominance is the presence of proactive and enabling regulatory frameworks, particularly in the United States. The U.S. Food and Drug Administration (FDA) has played a critical role in accelerating the adoption of digital pathology by expanding and streamlining approvals for Whole Slide Imaging (WSI) systems. These regulatory clearances have made it possible for WSI technologies to be used for primary diagnostic purposes, rather than being limited to research or secondary review applications.

Leading Market Participants

  • 3DHISTECH Ltd.
  • Apollo Enterprise Imaging Corp
  • Hamamatsu Photonics K.K.
  • Hoffmann-La Roche Ltd.
  • Huron Technologies International Inc.
  • Koninklijke Philips N.V.
  • Sectra AB
  • Thermo Fisher Scientific Inc.
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Digital Pathology Market

Chapter 2. Research Methodology & Research Framework

  • 2.1. Research Objective
  • 2.2. Product Overview
  • 2.3. Market Segmentation
  • 2.4. Qualitative Research
    • 2.4.1. Primary & Secondary Sources
  • 2.5. Quantitative Research
    • 2.5.1. Primary & Secondary Sources
  • 2.6. Breakdown of Primary Research Respondents, By Region
  • 2.7. Assumption for Study
  • 2.8. Market Size Estimation
  • 2.9. Data Triangulation

Chapter 3. Global Digital Pathology Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Scanner & Whole-Slide-Imaging Hardware Manufacturers
    • 3.1.2. Image-Management & AI / Computational-Pathology Software Developers
    • 3.1.3. Cloud, Storage & Interoperability (LIS / EHR) Providers
    • 3.1.4. Distribution, Integration & Managed Pathology Services
    • 3.1.5. End Users (Hospitals & Diagnostic Labs, Pharma & Biotech, Academia, CROs)
  • 3.2. Industry Outlook
    • 3.2.1. Overview of the Global Digital & Computational Pathology Industry
    • 3.2.2. AI-Assisted Diagnosis, Whole-Slide Imaging & Telepathology Adoption
    • 3.2.3. Pathologist Shortages, Regulatory Clearances & Reimbursement Trends
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
    • 3.5.2. Price Trend Analysis, By Product

Chapter 4. Global Digital Pathology Market Analysis

  • 4.1. Competition Dashboard
    • 4.1.1. Market Concentration Rate
    • 4.1.2. Company Market Share Analysis (Value %), 2025
    • 4.1.3. Competitor Mapping & Benchmarking

Chapter 5. Global Digital Pathology Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.2.1. By Product
      • 5.2.1.1. Key Insights
        • 5.2.1.1.1. Hardware
          • 5.2.1.1.1.1. Scanners/Whole-Slide Imaging
          • 5.2.1.1.1.2. Slide Management Hardware
        • 5.2.1.1.2. Software
          • 5.2.1.1.2.1. Image Management
          • 5.2.1.1.2.2. AI/Computational Pathology
        • 5.2.1.1.3. Services & Storage
    • 5.2.2. By Type
      • 5.2.2.1. Key Insights
        • 5.2.2.1.1. Human Pathology
        • 5.2.2.1.2. Veterinary Pathology
    • 5.2.3. By Workflow
      • 5.2.3.1. Key Insights
        • 5.2.3.1.1. Primary Diagnosis
        • 5.2.3.1.2. Consultation/Telepathology
        • 5.2.3.1.3. Research & Education
    • 5.2.4. By Application
      • 5.2.4.1. Key Insights
        • 5.2.4.1.1. Diagnostics
        • 5.2.4.1.2. Drug Discovery & Development
        • 5.2.4.1.3. Academic Research
        • 5.2.4.1.4. Training & Education
    • 5.2.5. By End User
      • 5.2.5.1. Key Insights
        • 5.2.5.1.1. Hospitals & Diagnostic Labs
        • 5.2.5.1.2. Pharma & Biotech
        • 5.2.5.1.3. Academic & Research Institutes
        • 5.2.5.1.4. CROs
    • 5.2.6. By Region
      • 5.2.6.1. Key Insights
        • 5.2.6.1.1. North America
          • 5.2.6.1.1.1. The U.S.
          • 5.2.6.1.1.2. Canada
          • 5.2.6.1.1.3. Mexico
        • 5.2.6.1.2. Europe
          • 5.2.6.1.2.1. Western Europe
            • 5.2.6.1.2.1.1. The UK
            • 5.2.6.1.2.1.2. Germany
            • 5.2.6.1.2.1.3. France
            • 5.2.6.1.2.1.4. Italy
            • 5.2.6.1.2.1.5. Spain
            • 5.2.6.1.2.1.6. Rest of Western Europe
          • 5.2.6.1.2.2. Eastern Europe
            • 5.2.6.1.2.2.1. Poland
            • 5.2.6.1.2.2.2. Russia
            • 5.2.6.1.2.2.3. Rest of Eastern Europe
        • 5.2.6.1.3. Asia Pacific
          • 5.2.6.1.3.1. China
          • 5.2.6.1.3.2. India
          • 5.2.6.1.3.3. Japan
          • 5.2.6.1.3.4. Australia & New Zealand
          • 5.2.6.1.3.5. South Korea
          • 5.2.6.1.3.6. ASEAN
          • 5.2.6.1.3.7. Rest of Asia Pacific
        • 5.2.6.1.4. Middle East & Africa (MEA)
          • 5.2.6.1.4.1. Saudi Arabia
          • 5.2.6.1.4.2. South Africa
          • 5.2.6.1.4.3. UAE
          • 5.2.6.1.4.4. Rest of MEA
        • 5.2.6.1.5. South America
          • 5.2.6.1.5.1. Argentina
          • 5.2.6.1.5.2. Brazil
          • 5.2.6.1.5.3. Rest of South America

Chapter 6. North America Market Analysis

  • 6.1. Market Dynamics and Trends
    • 6.1.1. Growth Drivers
    • 6.1.2. Restraints
    • 6.1.3. Opportunity
    • 6.1.4. Key Trends
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. Key Insights
      • 6.2.1.1. By Product
      • 6.2.1.2. By Type
      • 6.2.1.3. By Workflow
      • 6.2.1.4. By Application
      • 6.2.1.5. By End User
      • 6.2.1.6. By Country

Chapter 7. Europe Market Analysis

  • 7.1. Market Dynamics and Trends
    • 7.1.1. Growth Drivers
    • 7.1.2. Restraints
    • 7.1.3. Opportunity
    • 7.1.4. Key Trends
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. Key Insights
      • 7.2.1.1. By Product
      • 7.2.1.2. By Type
      • 7.2.1.3. By Workflow
      • 7.2.1.4. By Application
      • 7.2.1.5. By End User
      • 7.2.1.6. By Country

Chapter 8. Asia Pacific Market Analysis

  • 8.1. Market Dynamics and Trends
    • 8.1.1. Growth Drivers
    • 8.1.2. Restraints
    • 8.1.3. Opportunity
    • 8.1.4. Key Trends
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. Key Insights
      • 8.2.1.1. By Product
      • 8.2.1.2. By Type
      • 8.2.1.3. By Workflow
      • 8.2.1.4. By Application
      • 8.2.1.5. By End User
      • 8.2.1.6. By Country

Chapter 9. Middle East & Africa Market Analysis

  • 9.1. Market Dynamics and Trends
    • 9.1.1. Growth Drivers
    • 9.1.2. Restraints
    • 9.1.3. Opportunity
    • 9.1.4. Key Trends
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. Key Insights
      • 9.2.1.1. By Product
      • 9.2.1.2. By Type
      • 9.2.1.3. By Workflow
      • 9.2.1.4. By Application
      • 9.2.1.5. By End User
      • 9.2.1.6. By Country

Chapter 10. South America Market Analysis

  • 10.1. Market Dynamics and Trends
    • 10.1.1. Growth Drivers
    • 10.1.2. Restraints
    • 10.1.3. Opportunity
    • 10.1.4. Key Trends
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. Key Insights
      • 10.2.1.1. By Product
      • 10.2.1.2. By Type
      • 10.2.1.3. By Workflow
      • 10.2.1.4. By Application
      • 10.2.1.5. By End User
      • 10.2.1.6. By Country

Chapter 11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 11.1. 3DHISTECH Ltd.
  • 11.2. Apollo Enterprise Imaging Corp
  • 11.3. Hamamatsu Photonics K.K.
  • 11.4. Hoffmann-La Roche Ltd.
  • 11.5. Huron Technologies International Inc.
  • 11.6. Koninklijke Philips N.V.
  • 11.7. Sectra AB
  • 11.8. Thermo Fisher Scientific Inc.
  • 11.9. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators